KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Equity Average (2016 - 2026)

Neogenomics filings provide 16 years of Equity Average readings, the most recent being $832.7 million for Q1 2026.

  • On a quarterly basis, Equity Average fell 7.0% to $832.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $832.7 million, a 7.0% decrease, with the full-year FY2025 number at $869.5 million, down 5.69% from a year prior.
  • Equity Average hit $832.7 million in Q1 2026 for Neogenomics, down from $837.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $1.1 billion in Q1 2022 to a low of $832.7 million in Q1 2026.
  • Median Equity Average over the past 5 years was $932.5 million (2024), compared with a mean of $940.3 million.
  • The widest YoY moves for Equity Average: up 41.96% in 2022, down 10.44% in 2022.
  • Neogenomics' Equity Average stood at $1.0 billion in 2022, then dropped by 6.07% to $944.5 million in 2023, then decreased by 4.15% to $905.3 million in 2024, then decreased by 7.49% to $837.4 million in 2025, then dropped by 0.57% to $832.7 million in 2026.
  • The last three reported values for Equity Average were $832.7 million (Q1 2026), $837.4 million (Q4 2025), and $846.2 million (Q3 2025) per Business Quant data.